Cerebral Vasospasm Market size was over USD 2.7 billion in 2024 and is estimated to reach USD 5.7 billion by the end of 2037, expanding at a CAGR of 6.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of cerebral vasospasm is evaluated at USD 2.8 billion.
Subarachnoid hemorrhage (SAH) remains a leading cause of cerebral vasospasm, with increasing incidences driven by aging populations, lifestyle factors, and hypertension, fueling demand for effective treatments and preventive care. According to the NLM, published in December 2024, the global incidence of subarachnoid hemorrhage (SAH) among adolescents and young adults (AYAs) rose by 12.6% from 1990 to 2021, increasing from 109,120 cases in 1990 to 122,822 cases in 2021. Advancements in imaging technologies like transcranial Doppler ultrasound, CT angiography, and MR angiography are crucial for the early detection and monitoring of vasospasm. These tools enable timely interventions that enhance patient outcomes and drive growth in the cerebral vasospasm market.
The market is experiencing significant growth due to innovative treatments like clazosentan, a selective endothelin receptor antagonist, and Rho-kinase inhibitors such as fasudil. In January 2025, Woolsey Pharmaceuticals announced that the U.S. Patent and Trademark Office granted additional claims for BRAVYL (oral fasudil) in treating ALS. Additionally, minimally invasive endovascular procedures like balloon angioplasty and intra-arterial vasodilator therapy are gaining traction for effectively managing vasospasm. These advancements in pharmacological and interventional treatments are driving cerebral vasospasm market expansion by providing more effective and less invasive solutions for patients with cerebral vasospasm.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 2.7 billion |
|
Forecast Year Market Size (2037) |
USD 5.7 billion |
|
Regional Scope |
|
End Users (Hospitals, Clinics, Ambulatory surgical centers, Trauma Centers, Emergency Departments)
By end user, the trauma center segment is expected to hold over 43.8% cerebral vasospasm market share by the end of 2037. The segment is growing due to the increasing number of traumatic brain injuries (TBI). The CDC estimates that there were roughly 69,473 TBI-related deaths in 2021 and 214,110 TBI-related hospitalizations in 2020A. These often lead to subarachnoid hemorrhage (SAH) and subsequent cerebral vasospasm. As trauma centers specialize in managing severe cases, including TBI and SAH, their expertise and resources contribute to the demand for advanced diagnostic and therapeutic treatments for cerebral vasospasm. Additionally, the adoption of minimally invasive procedures and improved treatment protocols in trauma centers is further driving the market’s growth.
Diagnosis (Comoted tomography angiography, Digital subtraction Angiography, Magnetic Resonance Angiography, Transcranial Doppler)
Based on the diagnosis, the comoted tomography angiography segment is anticipated to hold the majority of the cerebral vasospasm market share over the forecast period. The segment’s growth is attributed to the accuracy in detecting subarachnoid hemorrhage (SAH), a leading cause of vasospasm. Advanced CT angiography and perfusion imaging provide detailed vascular assessments, enabling early diagnosis and precise monitoring of cerebral vasospasm. Its widespread availability, non-invasive nature, and rapid imaging capabilities make CT a preferred diagnostic tool in emergency and routine settings, driving its adoption and contributing to cerebral vasospasm market growth for cerebral vasospasm management.
Our in-depth analysis of the global market includes the following segments:
|
End User |
|
|
Diagnosis |
|
|
Treatment |
|
North America Market Statistics
North America cerebral vasospasm market is projected to capture revenue share of around 47.3% by the end of 2037. The increasing prevalence of subarachnoid hemorrhage (SAH) in North America, driven by aging populations and lifestyle factors such as hypertension and smoking, is boosting demand for effective cerebral vasospasm treatments. As SAH is a leading cause of vasospasm, its rising incidence directly impacts market growth. Additionally, higher healthcare spending in the region is improving access to advanced diagnostic and therapeutic options. These factors together enhance treatment accessibility and foster significant growth in the market.
The U.S. cerebral vasospasm market is experiencing substantial growth due to the rise in minimally invasive procedures, such as balloon angioplasty and intra-arterial vasodilator therapy, which offer effective solutions with reduced recovery times and fewer complications. Significant investments are advancing new therapies, including endothelin receptor antagonists and innovative endovascular treatments. A report by Research! America from January 2022 reveals that BARDA investments surged from USD 562 million in 2019 to USD 4.0 billion in 2020, while other health R&D sources accounted for under 10% of the total. These factors together are enhancing treatment options, improving outcomes, and driving the market’s expansion.
The continuous investments in healthcare infrastructure by the government of Canada have enhanced access to advanced cerebral vasospasm treatments by supporting the adoption of new technologies and therapies. This funding has improved treatment availability and affordability, driving cerebral vasospasm market growth. In October 2024, the Pan American Health Organization reported that the Government pledged nearly USD 200 billion over ten years for provincial and territorial health funding. Heightened awareness among healthcare professionals and the public, aided by health campaigns, is resulting in earlier diagnosis and better management of cerebral vasospasm, thereby boosting the market in Canada.
Asia Pacific Market Analysis
In APAC, the cerebral vasospasm market is poised to garner lucrative revenue share over the forecast period. The improvement of diagnostic technologies such as transcranial Doppler ultrasound, CT angiography, and MR angiography in the Asia Pacific region is enhancing the early detection and monitoring of cerebral vasospasm. Early diagnosis facilitates more effective treatments and better outcomes, driving the demand for advanced diagnostic equipment. Additionally, significant investments in healthcare infrastructure across the region are improving access to medical treatments and equipping hospitals with cutting-edge technologies, ensuring better diagnosis and treatment options, thus fueling cerebral vasospasm market growth.
The government of China made significant investments in healthcare infrastructure, including building new hospitals and upgrading facilities, improving access to advanced diagnostic and therapeutic treatments for cerebral vasospasm, and fueling market growth. For instance, in May 2023, the Chinese government established a healthcare insurance system that covers nearly 96% of the population, benefiting over 1.3 billion people. Increased investments in cerebrovascular research by the government and private sectors are leading to innovative treatments, enhancing effectiveness, and improving patient outcomes, thereby accelerating the growth of the cerebral vasospasm market in China.
The adoption of advanced diagnostic tools, such as transcranial doppler, and MR angiography, is enhancing the detection and monitoring of cerebral vasospasm in India, enabling early diagnosis and timely interventions. This improves patient outcomes and drives demand for diagnostic services. Additionally, increased investment from both the government and private pharmaceutical companies in cerebrovascular research is fostering the development of innovative therapies. In August 2024, the Ministry of Chemicals and Fertilizers reported that drug and pharmaceutical exports in India increased by 8.3% from USD 2.1 billion in July 2023 to USD 2.3 billion in July 2024. The availability of novel drugs and advanced treatments further contribute to the expansion of the cerebral vasospasm market.
Key companies in the cerebral vasospasm market are driving innovation through the development of novel therapies and advanced diagnostic tools. Pharmaceutical companies are introducing innovative drugs, such as endothelin receptor antagonists and Rho-kinase inhibitors, which offer enhanced efficacy for treating cerebral vasospasm. In April 2024, Nxera Pharma Co. Ltd, previously Sosei Group, announced an exclusive agreement with Handok Inc. to distribute PIVLAZ (clazosentan sodium) 150 mg in South Korea. Additionally, advances in diagnostic technologies like transcranial Doppler ultrasound and MR angiography are improving early detection and patient outcomes. Some of the key players are:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?